Dr Doerflinger completed a Master of Science Degree with focus on Biochemistry and Immunology at the University of Stuttgart, Germany. Dr Doerflinger then moved to Australia in February 2012 to undertake PhD studies under the supervision of Associate Professor Hamsa Puthalakath at La Trobe University, and their work on cell death regulation resulted in several first author publications.
In 2016, they took up a position as Postdoctoral Fellow in the Pellegrini laboratory at WEHI, where they expanded their skillset and career focus towards translational outcomes and have built productive collaborative networks nationally (such as The Peter Doherty Institute, Hudson Institute, La Trobe University, Peter MacCallum Cancer Centre, MCRI and The Florey) and internationally (Austria, Germany, Japan, US).
Dr Doerflinger has recently been appointed Laboratory Head at WEHI and in this role oversees the PC3 facility within the Infectious Diseases and Immune Defense division. This is the basis to lead a comprehensive research program in which Dr Doerflinger continues to uncover the regulatory processes of programmed cell death processes and their contribution to shaping immune responses to infection.
Australia, La Trobe University, PhD, 2015
Germany, University of Stuttgart, MSc, 2009
Scotland, University of Edinburgh, BSc (Thesis), 2008
1. Preston, S.P., Stutz, M.D., Allison, C.C., Nachbur, U., Gouil, Q., Tran, B.M., Duvivier, V., Arandjelovic, P., Cooney, J.P., Mackiewicz, L., Meng, Y., Schaefer, J., Bader, S.M., Peng, H., Valaydon, Z., Rajasekaran, P., Jennison, C., Lopaticki, S., Farrell, A., Ryan, M., Howell, J., Croagh, C., Karunakaran, D., Schuster-Klein, C., Murphy, J.M., Fifis, T., Christophi, C., Vincan, E., Blewitt, M.E., Thompson, A., Boddey, J.A., #Doerflinger, M., #Pellegrini, M.
#joint senior author
Epigenetic Silencing of RIPK3 in Hepatocytes Prevents MLKL-mediated Necroptosis From Contributing to Liver Pathologies.
Gastroenterology, (2022)163(6) 1643-1657.e14
2.Haeusler, G.M., Garnham, A.L., Li-Wai-Suen, C.S.N., Clark, J.E., Babl, F.E., Allaway, Z., Slavin, M.A., Mechinaud, F., Smyth, G.K., Phillips, B., #Thursky, K.A., #Pellegrini, M., #Doerflinger, M.
#joint senior author
Blood transcriptomics identifies immune signatures indicative of infectious complications in childhood cancer patients with febrile neutropenia.
Clinical and Translational Immunology,(2022) 11(5)
3. Stutz, M.D., Allison, C.C., Ojaimi, S., Preston, S.P., Doerflinger, M., Arandjelovic, P., Whitehead, L., Bader, S.M., Batey, D., Asselin-Labat, M.-L., Herold, M.J., Strasser, A., West, N.P., Pellegrini, M.
Macrophage and neutrophil death programs differentially confer resistance to tuberculosis.
Immunity, (2021) 54(8) 1758-1771.e7
4. Doerflinger, M., Haeusler, G.M., Li-Wai-Suen, C.S.N., Clark, J.E., Slavin, M., Babl, F.E., Allaway, Z., Mechinaud, F., Smyth, G.K., De Abreu Lourenco, R., Phillips, B., Pellegrini, M., Thursky, K.A.
Procalcitonin and Interleukin-10 May Assist in Early Prediction of Bacteraemia in Children With Cancer and Febrile Neutropenia.
Frontiers in Immunology, (2021)12,641879
5. Doerflinger, M., Deng, Y., Whitney, P., Salvamoser, R., Engel, S., Kueh, A.J., Tai, L., Bachem, A., Gressier, E., Geoghegan, N.D., Wilcox, S., Rogers, K.L., Garnham, A.L., Dengler, M.A., Bader, S.M., Ebert, G., Pearson, J.S., De Nardo, D., Wang, N., Yang, C., Pereira, M., Bryant, C.E., Strugnell, R.A., Vince, J.E., Pellegrini, M., Strasser, A., Bedoui, S., Herold, M.J. (2020).
Flexible Usage and Interconnectivity of Diverse Cell Death Pathways Protect against Intracellular Infection. Immunity,53(3) 533-547.e7
Mycobacterium tuberculosis (Mtb) chronically infects phagocytes in the lung, and our project aims at developing novel RNA-based therapeutics that disarm Mtbs armoury of virulence factors and induce apoptosis to boost immunity.
Team members: Jan Schafer (PhD student), George Ashdown (Postdoc)
Programmed cell death and inflammation appear to be involved in COVID-19 disease outcomes, and our project aims to identify which key players contribute to or mitigate pathology and present avenues for therapeutic intervention.
Team member: Stefanie Bader (PhD student)
Despite the success of antiretroviral therapy (ART) in suppressing acute HIV infection, there is no curative intervention that rids the body of the latent HIV reservoir. Our strategy of inducing cell death to kill this ‘needle in a haystack’ aims to overcome the lifelong treatment of patients with a pill every day.
Team members: Le Wang (PhD student), Kathryn Davidson (Postdoc)
Dengue fever is a vector borne viral disease and an increasing global health threat that necessitates the urgent development of new therapies. The most severe symptoms of Dengue appear to a result of dysregulated host immune response, and our work aims to understand the host factors that drive disease and to identify novel treatment targets.
Team members: William Clow (PhD student)
HTLV-1 is a virus that causes severe disease sequelae including leukemia, myelopathy and secondary bacterial lung infections. HTLV-1 is highly endemic in remote indigenous communities in rural Australia, There is no treatment and no point-of-care diagnostic tests available to detect this pathogen in the field.
Team members: Lewis Williams (Postdoc)
Cancer patients are at increased risk of infection due to immunesupression as a result of their chemotherapy. Tests that can identify the patients at risk of severe infectious complications will enable rapid and customized treatment.
Team members: Lewis Williams (Postdoc) and Clinican PhD students from the Peter MacCallum Cancer Centre